Panbela Therapeutics EV/Sales
Что обозначает EV/Sales в Panbela Therapeutics?
EV/Sales Panbela Therapeutics Inc. является N/A
Какое определение для EV/Sales?
Enterprise value to sales ratio compares a company’s total value to its sales.
ttm (trailing twelve months)
Enterprise value/sales is a valuation ratio that compares the company's enterprise value to its annual sales. It indicates the company's capacity to generate free cash flow. In general, the lower the ratio, the cheaper the company is.
EV/Sales is most often calculated as cash and cash equivalents subtracted from the sum of market capitalization and debt and divided by annual sales. Many analysts consider EV/sales to be a more accurate metric than Price/Sales as it considers both debt and equity holders in its calculation. One of the limitations of the calculation is that sales do not take into account a company's taxes or expenses.
Что делает Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.